Literature DB >> 8219203

Incidence of Waldenström's macroglobulinemia.

L J Herrinton1, N S Weiss.   

Abstract

This study sought to determine the incidence and pattern of occurrence of Waldenström's macroglobulinemia, a plasmacytoid lymphocyte malignancy that involves monoclonal production of the IgM M-component type. Cases with Waldenström's macroglobulinemia have been reported since 1978 to the population-based cancer registry that serves western Washington state, and since 1988 to the eight other cancer registries that participate in the National Cancer Institute's Surveillance, Epidemiology, and End-Results program. Persons less than 85 years old newly diagnosed with Waldenström's macroglobulinemia were identified through 1989. The age-standardized annual incidence rate was 6.1 per million in white men and 2.5 per million in white women (1980 US standard). Only five cases were reported in black women, among whom the age-standardized annual incidence rate was 3.6 per million. No cases were reported among black men (5.8 cases expected, based on the rates in white men); this finding may be due to chance, underdiagnosis of Waldenström's macroglobulinemia in this group, or may reflect a truly low rate. Further investigation of a large, racially diverse population is required to better characterize the epidemiology of this rare disease.

Entities:  

Mesh:

Year:  1993        PMID: 8219203

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  21 in total

1.  Obesity is associated with an increased risk of monoclonal gammopathy of undetermined significance among black and white women.

Authors:  Ola Landgren; S Vincent Rajkumar; Ruth M Pfeiffer; Robert A Kyle; Jerry A Katzmann; Angela Dispenzieri; Qiuyin Cai; Lynn R Goldin; Neil E Caporaso; Joseph F Fraumeni; William J Blot; Lisa B Signorello
Journal:  Blood       Date:  2010-04-26       Impact factor: 22.113

2.  Evolution of Management and Outcomes in Waldenström Macroglobulinemia: A Population-Based Analysis.

Authors:  Adam J Olszewski; Steven P Treon; Jorge J Castillo
Journal:  Oncologist       Date:  2016-07-29

3.  Novel agents in Waldenström macroglobulinemia.

Authors:  Ghayas C Issa; Irene M Ghobrial; Aldo M Roccaro
Journal:  Clin Investig (Lond)       Date:  2011

4.  New Therapeutic Approaches for Waldenstrom Macroglobulinemia.

Authors:  Jennifer Stedman; Aldo Roccaro; Xavier Leleu; Irene M Ghobrial
Journal:  Drugs Future       Date:  2010-01       Impact factor: 0.148

5.  Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia.

Authors:  Irene M Ghobrial; Morie Gertz; Betsy Laplant; John Camoriano; Suzanne Hayman; Martha Lacy; Stacey Chuma; Brianna Harris; Renee Leduc; Meghan Rourke; Stephen M Ansell; Daniel Deangelo; Angela Dispenzieri; Leif Bergsagel; Craig Reeder; Kenneth C Anderson; Paul G Richardson; Steven P Treon; Thomas E Witzig
Journal:  J Clin Oncol       Date:  2010-02-08       Impact factor: 44.544

6.  Immune-related and inflammatory conditions and risk of lymphoplasmacytic lymphoma or Waldenstrom macroglobulinemia.

Authors:  Sigurdur Y Kristinsson; Jill Koshiol; Magnus Björkholm; Lynn R Goldin; Mary L McMaster; Ingemar Turesson; Ola Landgren
Journal:  J Natl Cancer Inst       Date:  2010-02-24       Impact factor: 13.506

7.  microRNA expression in the biology, prognosis, and therapy of Waldenström macroglobulinemia.

Authors:  Aldo M Roccaro; Antonio Sacco; Changzhong Chen; Judith Runnels; Xavier Leleu; Feda Azab; Abdel Kareem Azab; Xiaoying Jia; Hai T Ngo; Molly R Melhem; Nicholas Burwick; Lyuba Varticovski; Carl D Novina; Barrett J Rollins; Kenneth C Anderson; Irene M Ghobrial
Journal:  Blood       Date:  2008-12-12       Impact factor: 22.113

8.  Novel agents in Waldenstrom Macroglobulinemia.

Authors:  Antonio Sacco; Xavier Leleu; Giuseppe Rossi; Irene M Ghobrial; Aldo M Roccaro
Journal:  Open J Hematol       Date:  2010-05-28

9.  Risk of lymphoproliferative disorders among first-degree relatives of lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia patients: a population-based study in Sweden.

Authors:  Sigurdur Y Kristinsson; Magnus Björkholm; Lynn R Goldin; Mary L McMaster; Ingemar Turesson; Ola Landgren
Journal:  Blood       Date:  2008-08-13       Impact factor: 22.113

Review 10.  Update on therapeutic options in Waldenström macroglobulinemia.

Authors:  Xavier Leleu; Julie Gay; Aldo M Roccaro; Anne-Sophie Moreau; Stephanie Poulain; Remy Dulery; Berenice Bro Des Champs; Daniela Robu; Irene M Ghobrial
Journal:  Eur J Haematol       Date:  2009-01       Impact factor: 2.997

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.